Kimberly E Sawyer
Datos Biográficos
| ID | 8306540 |
|---|---|
| NOMBRE | Kimberly E Sawyer |
| NOMBRES | Kimberly E |
| APELLIDO | Sawyer |
| FIRMA | SAWYER K E |
| AFILIACIONES | University of Washington |
| ORCID | 0000-0002-3498-4584 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2020 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2026 |
| ÍNDICE H | 0 |
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
How Should Adolescent Health Decision-Making Authority Be Shared
Shared decision making (SDM) is used in adult and pediatric practice for both its ethical and its practical benefits. However, its use is complicated with adolescents whose emerging and relational autonomy is distinct from that of adults, who make decisions independently, and children, whose parents make decisions for them. This hypothetical case scenario and commentary provide clinicians with a practical and stepwise approach to SDM with adolesc…
Sin obras prominentes en esta página.
How Should Adolescent Health Decision-Making Authority Be Shared
Shared decision making (SDM) is used in adult and pediatric practice for both its ethical and its practical benefits. However, its use is complicated with adolescents whose emerging and relational autonomy is distinct from that of adults, who make decisions independently, and children, whose parents make decisions for them. This hypothetical case scenario and commentary provide clinicians with a practical and stepwise approach to SDM with adolesc…
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
Ethics and Legal Issues in Pediatric Healthcare (2 obras) · Best interests (1 obras) · Cystic fibrosis (1 obras) · Cystic Fibrosis Research Advances (1 obras) · Cystic fibrosis transmembrane conductance regulator (1 obras) · Disease (1 obras) · Do no harm (1 obras) · Ethics in medical practice (1 obras) · Genetic testing (1 obras) · Harm (1 obras)